What You Should Know:
– Amalgam Rx, a company specializing in data-driven healthcare decision-making, has announced a $20M credit investment from Catalio Capital Management.
– The $20M senior secured term loan provides Amalgam with an initial draw of $12M to support its market expansion and refinance existing corporate debt. The credit investment also gives Amalgam access to Catalio’s extensive network of life sciences leaders, including its board of advisors and over 45 Catalio Venture Partners. These partners are composed of renowned scientist-entrepreneurs who will provide strategic insights to support product development and commercial growth.
Prioritizing Safety and Integrity in Medical AI
As AI becomes more integrated into healthcare, ensuring its safety, compliance, and integrity is of the utmost importance. Amalgam has spent five years developing its proprietary Medical-Grade AI platform, which is engineered with built-in safeguards to meet rigorous clinical, ethical, and regulatory standards. This technology allows healthcare organizations to safely, quickly, and confidently harness the power of AI. The funding will be used to accelerate the scaling of Amalgam’s Medical-Grade AI solutions, which are designed to empower both patients in their daily lives and providers in their clinical workflows.
Ryan Sysko, CEO of Amalgam Rx, noted that Catalio’s “deep expertise in healthcare and life sciences, combined with their expansive venture network, makes them an ideal partner as we scale”. He stated that the funding will accelerate the development and deployment of the company’s AI platform, ultimately advancing its mission to transform chronic disease management through intelligent, personalized care.
